The influence of natural substrates and inhibitors on the nucleotide-dependent excision activity of HIV-1 reverse transcriptase in the infected cell

Current Pharmaceutical Design

Volumn 12, Issue 15, 2006, Pages 1827-1841

  Smith, Anthony James ^a   Scott, Walter Alvin ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

AZT resistance mutations; HIV 1 reverse transcriptase; Macrophages; Nucleotide excision; Primer unblocking activity; Pyrophosphate; TAMs

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTIRETROVIRUS AGENT; DIDANOSINE; INORGANIC PYROPHOSPHATASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; T LYMPHOCYTE RECEPTOR; TENOFOVIR; ZIDOVUDINE;

AMINO ACID SEQUENCE; BINDING SITE; CELL POPULATION; CELLULAR DISTRIBUTION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE INSERTION; GENE MUTATION; GENETIC CODE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IN VITRO STUDY; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE ACTIVATION; VIRUS REPLICATION; VIRUS RESISTANCE;

DNA REPAIR; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; NUCLEOTIDES; REVERSE TRANSCRIPTASE INHIBITORS; SUBSTRATE SPECIFICITY;

EID: 33646519924     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873572     Document Type: Review

References (182)

1. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185-91.
2. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-4.
3. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155-8.
4. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89: 1934-8.
5. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis 1994; 170: 1157-64.
6. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin J-L, et al. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. AIDS 1999; 13: 1705-9.
7. Larder BA, Coates KE, Kemp SD. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 1991; 65: 5232-6.
8. Arion D, Kaushik N, McCormick S, Borkow G, Parniak MA. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry 1998; 37: 15908-17.
9. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95: 13471-6.
10. Meyer PR, Matsuura SE, Mian AM, So AG, Scott WA. A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999; 4: 35-43.
11. Matamoros T, Deval J, Guerreiro C, Mulard L, Canard B, Menéndez-Arias L. Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by α-phosphate-modified thymidine analogues. J Mol Biol 2005; 349: 451-63.
12. Scott WA. The enzymatic basis for thymidine analogue resistance in HIV-1. AIDS Rev 2001; 3: 194-200.
13. Ray AS, Murakami E, Basavapathruni A, Vaccaro JA, Ulrich D, Chu CK, et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003; 42: 8831-41.
14. Lennerstrand J, Hertogs K, Stammers DK, Larder BA. Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol 2001; 75: 7202-5.
15. Meyer PR, Matsuura SE, Zonarich D, Chopra RR, Pendarvis E, Bazmi HZ, et al. Relationship between 3′-azido-3′-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase. J Virol 2003; 77: 6127-37.
16. Meyer PR, Matsuura SE, Schinazi RF, So AG, Scott WA. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates. Antimicrob Agents Chemother 2000; 44: 3465-72.
17. Meyer PR, Matsuura SE, Tolun AA, Pfeifer I, So AG, Mellors JW, et al . Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46: 1540-5.
18. Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74: 3579-85.
19. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75: 4832-42.
20. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol 2002; 76: 9143-51.
21. Boyer PL, Imamichi T, Sarafianos SG, Arnold E, Hughes SH. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision. J Virol 2004; 78: 9987-97.
22. Naeger LK, Margot NA, Miller MD. ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002; 46: 2179-84.
23. Meyer PR, Lennerstrand J, Matsuura SE, Larder BA, Scott WA. Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation. J Virol 2003; 77: 3871-7.
24. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, Naeger LK, et al. Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 2004; 48: 992-1003.
25. Meyer PR, Smith AJ, Matsuura SE, Scott WA. Effects of primer-template sequence on ATP-dependent removal of chain-terminating nucleotide analogues by HIV-1 reverse transcriptase. J Biol Chem 2004; 279: 45389-98.
26. Isel C, Ehresmann C, Walter P, Ehresmann B, Marquet R. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J Biol Chem 2001; 276: 48725-32.
27. Mas A, Vázquez-Alvarez BM, Domingo E, Menéndez-Arias L. Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol 2002; 323: 181-97.
28. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998; 102: 1769-75.
29. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, Miller V, et al. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrob Agents Chemother 1999; 43: 1961-7.
30. Mas A, Parera M, Briones C, Soriano V, Martínez MA, Domingo E, et al. Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J 2000; 19: 5752-61.
31. Rigourd M, Ehresmann C, Parniak MA, Ehresmann B, Marquet R. Primer unblocking and rescue of DNA synthesis by azidothymidine (AZT)-resistant HIV-1 reverse transcriptase: comparison between initiation and elongation of reverse transcription and between (-) and (+) strand DNA synthesis. J Biol Chem 2002; 277: 18611-8.
32. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci USA 2005; 102: 2093-8.
33. Marchand B, Götte M. Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance. J Biol Chem 2003; 278: 35362-72.
34. Sluis-Cremer N, Arion D, Parikh U, Koontz D, Schinazi RF, Mellors JW, et al. The 3′-azido group is not the primary determinant of AZT responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem 2005; 280: 29047-52.
35. Tong W, Lu CD, Sharma SK, Matsuura S, So AG, Scott WA. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Biochemistry 1997; 36: 5749-57.
36. Gao HQ, Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase. J Mol Biol 2000; 300: 403-18.
37. Sharma B, Kaushik N, Singh K, Kumar S, Pandey VN. Substitution of conserved hydrophobic residues in motifs B and C of HIV-1 RT alters the geometry of its catalytic pocket. Biochemistry 2002; 41: 15685-97.
38. Sharma B, Kaushik N, Upadhyay A, Tripathi S, Singh K, Pandey VN. A positively charged side chain at position 154 on the β8-αE loop of HIV-1 RT is required for stable ternary complex formation. Nucleic Acids Res 2003; 31: 5167-74.
39. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998; 282: 1669-75.
40. Sarafianos SG, Clark AD, Jr., Tuske S, Squire CJ, Das K, Sheng D, et al. Trapping HIV-1 reverse transcriptase before and after translocation on DNA. J Biol Chem 2003; 278: 16280-8.
41. Canard B, Sarfati SR, Richardson CC. Enhanced binding of azidothymidine-resistant human immunodeficiency virus 1 reverse transcriptase to the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer. J Biol Chem 1998; 273: 14596-604.
42. Sluis-Cremer N, Arion D, Parniak MA. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci 2000; 57: 1408-22.
43. Goldschmidt V, Marquet R. Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol 2004; 36: 1687-705.
44. Goff SP. Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. J Gene Med 2001; 3: 517-28.
45. Bukrinsky MI, Sharova N, McDonald TL, Pushkarskaya T, Tarpley WG, Stevenson M. Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. Proc Natl Acad Sci USA 1993; 90: 6125-9.
46. Karageorgos L, Li P, Burrell C. Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Res Hum Retroviruses 1993; 9: 817-23.
47. Zhang H, Zhang Y, Spicer T, Henrard D, Poiesz BJ. Nascent human immunodeficiency virus type 1 reverse transcription occurs within an enveloped particle. J Virol 1995; 69: 3675-82.
48. Zhang H, Dornadula G, Orenstein J, Pomerantz RJ. Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. J Hum Virol 2000; 3: 165-72.
49. Fassati A, Goff SP. Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. J Virol 2001; 75: 3626-35.
50. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, et al. Visualization of the intracellular behavior of HIV in living cells. J Cell Biol 2002; 159: 441-52.
51. Nermut MV, Fassati A. Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. J Virol 2003; 77: 8196-206.
52. Fouchier RA, Malim MH. Nuclear import of human immunodeficiency virus type-1 preintegration complexes. Adv Virus Res 1999; 52: 275-99.
53. Miller MD, Farnet CM, Bushman FD. Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. J Virol 1997; 71: 5382-90.
54. Grewe C, Beck A, Gelderblom HR. HIV: early virus-cell interactions. J Acquir Immune Defic Syndr 1990; 3: 965-74.
55. Smith AJ, Meyer PR, Asthana D, Ashman MR, Scott WA. Intracellular substrates for the primer-unblocking reaction by human immunodeficiency virus type 1 reverse transcriptase: detection and quantitation in extracts from quiescent- and activated-lymphocyte subpopulations. Antimicrob Agents Chemother 2005; 49: 1761-9.
56. Ray AS, Basavapathruni A, Anderson KS. Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir. J Biol Chem 2002; 277: 40479-90.
57. Goday A, Simmonds HA, Webster DR, Levinsky RJ, Watson AR, Hoffbrand AV. Importance of platelet-free preparations for evaluating lymphocyte nucleotide levels in inherited or acquired immunodeficiency syndromes. Clin Sci (Lond) 1983; 65: 635-43.
58. Verity MA, Tam CF, Cheung MK, Mock DC, Walford RL. Delayed phytohemagglutinin-stimulated production of adenosine triphosphate by aged human lymphocytes: possible relation to mitochondrial dysfunction. Mech Ageing Dev 1983; 23: 53-65.
59. Pilz RB, Willis RC, Boss GR. The influence of ribose 5-phosphate availability on purine synthesis of cultured human lymphoblasts and mitogen-stimulated lymphocytes. J Biol Chem 1984; 259: 2927-35.
60. De La Rosa J, Kotb M, Kredich NM. Regulation of S-adenosylmethionine synthetase activity in cultured human lymphocytes. Biochim Biophys Acta 1991; 1077: 225-32.
61. Traut TW. Physiological concentrations of purines and pyrimidines. Mol Cell Biochem 1994; 140: 1-22.
62. Fairbanks LD, Bofill M, Ruckemann K, Simmonds HA. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans. Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors. J Biol Chem 1995; 270: 29682-9.
63. Guynn RW, Veloso D, Lawson JW, Veech RL. The concentration and control of cytoplasmic free inorganic pyrophosphate in rat liver in vivo. Biochem J 1974; 140: 369-75.
64. Russell RG. Metabolism of inorganic pyrophosphate (PPi). Arthritis Rheum 1976; 19(Suppl 3): 465-78.
65. Lust G, Seegmiller JE. A rapid, enzymatic assay for measurement of inorganic pyrophosphate in biological samples. Clin Chim Acta 1976; 66: 241-9.
66. Rachow JW, Ryan L M. Inorganic pyrophosphate metabolism in arthritis. Rheum Dis Clin North Am 1988; 14: 289-302.
67. Barshop BA, Adamson DT, Vellom DC, Rosen F, Epstein BL, Seegmiller JE. Luminescent immobilized enzyme test systems for inorganic pyrophosphate: assays using firefly luciferase and nicotinamide-mononucleotide adenylyl transferase or adenosine-5′-triphosphate sulfurylase. Anal Biochem 1991; 197: 266-72.
68. Silcox DC, Jacobelli S, McCarty DJ. Identification of inorganic pyrophosphate in human platelets and its release on stimulation with thrombin. J Clin Invest 1973; 52: 1595-600.
69. Ryan LM, Lynch MP, McCarty DJ. Inorganic pyrophosphate levels in blood platelets from normal donors and patients with calcium pyrophosphate dihydrate crystal deposition disease. Arthritis Rheum 1983; 26: 564-6.
70. Dzeja PP, Terzic A. Phosphotransfer networks and cellular energetics. J Exp Biol 2003; 206: 2039-47.
71. Buttgereit F, Burmester GR, Brand MD. Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. Biochem Pharmacol 2000; 59: 597-603.
72. Hardie DG, Hawley SA. AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 2001; 23: 1112-9.
73. Jones DP. Intracellular diffusion gradients of O2 and ATP. Am J Physiol 1986; 250: C663-75.
74. Moyer JD, Henderson JF. Compartmentation of intracellular nucleotides in mammalian cells. CRC Crit Rev Biochem 1985; 19: 45-61.
75. Gajewski CD, Yang L, Schon EA, Manfredi G. New insights into the bioenergetics of mitochondrial disorders using intracellular ATP reporters. Mol Biol Cell 2003; 14: 3628-35.
76. Terkeltaub RA. Inorganic pyrophosphate generation and disposition in pathophysiology. Am J Physiol Cell Physiol 2001; 281: C1-11.
77. Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry. 4 ed. New York: W. H. Freeman; 2004.
78. Nilsen T, Romslo I. Subcellular localization of transferrin and pyrophosphate in liver cells after perfusion in situ or incubation in vitro. Scand J Clin Lab Invest 1992; 52: 373-8.
79. Raja KB, Smith GP, Peters TJ. Subcellular localization and properties of alkaline inorganic pyrophosphatase in human polymorphonuclear leucocytes. Clin Chim Acta 1981; 117: 33-41.
80. Shatton JB, Williams A, Weinhouse S. Subcellular distribution of inorganic pyrophosphatase activity in various normal and neoplastic cell types. Cancer Res 1983; 43: 3742-7.
81. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, et al. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/ macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988; 168: 1111-25.
82. Terai C, Carson DA. Pyrimidine nucleotide and nucleic acid synthesis in human monocytes and macrophages. Exp Cell Res 1991; 193: 375-81.
83. Roy B, Beuneu C, Roux P, Buc H, Lemaire G, Lepoivre M. Simultaneous determination of pyrimidine or purine deoxyribonucleoside triphosphates using a polymerase assay. Anal Biochem 1999; 269: 403-9.
84. Gao WY, Shirasaka T, Johns DG, Broder S, Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993; 91: 2326-33.
85. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993; 90: 8925-8.
86. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent antihuman immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994; 269: 12633-8.
87. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, et al. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem 2004; 279: 51545-53.
88. van Furth R, Raeburn JA, van Zwet TL. Characteristics of human mononuclear phagocytes. Blood 1979; 54: 485-500.
89. Meltzer MS, Skillman DR, Hoover DL, Hanson BD, Turpin JA, Kalter DC, et al . Macrophages and the human immunodeficiency virus. Immunol Today 1990; 11: 217-23.
90. Siebert G. The limited contribution of the nuclear envelope to metabolic compartmentation. Biochem Soc Trans 1978; 6: 5-9.
91. Skoog L, Bjursell G. Nuclear and cytoplasmic pools of deoxyribonucleoside triphosphates in Chinese hamster ovary cells. J Biol Chem 1974; 249: 6434-8.
92. Bestwick RK, Mathews CK. Unusual compartmentation of precursors for nuclear and mitochondrial DNA in mouse L cells. J Biol Chem 1982; 257: 9305-8.
93. Leeds JM, Slabaugh MB, Mathews CK. DNA precursor pools and ribonucleotide reductase activity: distribution between the nucleus and cytoplasm of mammalian cells. Mol Cell Biol 1985; 5: 3443-50.
94. Hao Z, Cooney DA, Hartman NR, Perno CF, Fridland A, DeVico AL, et al . Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 1988; 34: 431-5.
95. Balzarini J. Effect of antimetabolite drugs of nucleotide metabolism on the anti-human immunodeficiency virus activity of nucleoside reverse transcriptase inhibitors. Pharmacol Ther 2000; 87: 175-87.
96. Perno CF, Yarchoan R, Balzarini J, Bergamini A, Milanese G, Pauwels R, et al . Different pattern of activity of inhibitors of the human immunodeficiency virus in lymphocytes and monocyte/macrophages. Antiviral Res 1992; 17: 289-304.
97. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995; 39: 2555-9.
98. Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, et al. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 1997; 62: 138-43.
99. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF. Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002; 55: 209-25.
100. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell lifespan, and viral generation time. Science 1996; 271:1582-6.
101. Schacker TW, Nguyen PL, Beilman GJ, Wolinsky S, Larson M, Reilly C, et al. Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest 2002; 110: 1133-9.
102. Eckstein DA, Penn ML, Korin YD, Scripture-Adams DD, Zack JA, Kreisberg JF, et al. HIV-1 actively replicates in naive CD4(+) T cells residing within human lymphoid tissues. Immunity 2001; 15: 671-82.
103. Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, et al. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002; 76: 707-16.
104. Chun TW, Justement JS, Lempicki RA, Yang J, Dennis G, Jr., Hallahan CW, et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100: 1908-13.
105. Lambotte O, Taoufik Y, de Goër MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 23: 114-9.
106. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986; 233: 1089-93.
107. Bodi I, Abraham AA, Kimmel PL. Macrophages in human immunodeficiency virus-associated kidney diseases. Am J Kidney Dis 1994; 24: 762-7.
108. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIV during opportunistic infections. Science 1997; 276: 1857-61.
109. Brodie SJ. Nonlymphoid reservoirs of HIV replication in children with chronic-progressive disease. J Leukoc Biol 2000; 68: 351-9.
110. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001; 98: 658-63.
111. Wang J, Crawford K, Yuan M, Wang H, Gorry PR, Gabuzda D. Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Infect Dis 2002; 185: 885-97.
112. Simmonds P, Balfe P, Peutherer JF, Ludlam CA, Bishop JO, Brown AJ. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers. J Virol 1990; 64: 864-72.
113. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995; 1: 1284-90.
114. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387: 183-8.
115. Haase AT. Population biology of HIV-1 infection: viral and CD4+ T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999; 17: 625-56.
116. Pantaleo G, Graziosi C, Butini L, Pizzo PA, Schnittman SM, Kotler DP, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991; 88: 9838-42.
117. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362: 355-8.
118. Stebbing J, Gazzard B, Douek DC. Where does HIV live? N Engl J Med 2004; 350: 1872-80.
119. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol 2000; 18: 665-708.
120. Dimitrov DS, Willey RL, Sato H, Chang LJ, Blumenthal R, Martin MA. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993; 67: 2182-90.
121. Aquaro S, Bagnarelli P, Guenci T, De Luca A, Clementi M, Balestra E, et al. Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol 2002; 68: 479-88.
122. Ascher MS, Sheppard HW. AIDS as immune system activation: a model for pathogenesis. Clin Exp Immunol 1988; 73: 165-7.
123. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev 2001; 14: 753-77.
124. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995; 69: 2977-88.
125. Zhou Y, Zhang H, Siliciano JD, Siliciano RF. Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells. J Virol 2005; 79: 2199-210.
126. Geiss GK, Bumgarner RE, An MC, Agy MB, van 't Wout AB, Hammersmark E, et al. Large-scale monitoring of host cell gene expression during HIV-1 infection using cDNA microarrays. Virology 2000; 266: 8-16.
127. Cicala C, Arthos J, Selig SM, Dennis G, Jr., Hosack DA, Van Ryk D, et al. HIV envelope induces a cascade of cell signals in nonproliferating target cells that favor virus replication. Proc Natl Acad Sci USA 2002; 99: 9380-5.
128. van 't Wout AB, Lehrman GK, Mikheeva SA, O'Keeffe GC, Katze MG, Bumgarner RE, et al. Cellular gene expression upon human immunodeficiency virus type 1 infection of CD4(+)-T-cell lines. J Virol 2003; 77: 1392-402.
129. Famularo G, Moretti S, Marcellini S, Nucera E, De Simone C. CD8 lymphocytes in HIV infection: helpful and harmful. J Clin Lab Immunol 1997; 49: 15-32.
130. Borkow G, Bentwich Z. Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy. Clin Microbiol Rev 2004; 17: 1012-30.
131. Fujii Y, Otake K, Tashiro M, Adachi A. Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 1996; 393: 93-6.
132. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, et al. Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000; 97: 11466-71.
133. Kinter AL, Umscheid CA, Arthos J, Cicala C, Lin Y, Jackson R, et al. HIV envelope induces virus expression from resting CD4+ T cells isolated from HIV-infected individuals in the absence of markers of cellular activation or apoptosis. J Immunol 2003; 170: 2449-55.
134. Kornfeld H, Cruikshank WW, Pyle SW, Berman JS, Center DM. Lymphocyte activation by HIV-1 envelope glycoprotein. Nature 1988; 335: 445-8.
135. Cicala C, Arthos J, Ruiz M, Vaccarezza M, Rubbert A, Riva A, et al. Induction of phosphorylation and intracellular association of CC chemokine receptor 5 and focal adhesion kinase in primary human CD4+ T cells by macrophage-tropic HIV envelope. J Immunol 1999; 163: 420-6.
136. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91: 664-8.
137. Alessandrini L, Santarcangelo AC, Olivetta E, Ferrantelli F, d'Aloja P, Pugliese K, et al. T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS. J Gen Virol 2000; 81: 2905-17.
138. Quaranta MG, Tritarelli E, Giordani L, Viora M. HIV-1 Nef induces dendritic cell differentiation: a possible mechanism of uninfected CD4(+) T cell activation. Exp Cell Res 2002; 275: 243-54.
139. Vendeville A, Rayne F, Bonhoure A, Bettache N, Montcourrier P, Beaumelle B. HIV-1 Tat enters T cells using coated pits before translocating from acidified endosomes and eliciting biological responses. Mol Biol Cell 2004; 15: 2347-60.
140. Briant L, Coudronnière N, Robert-Hebmann V, Benkirane M, Devaux C. Binding of HIV-1 virions or gp120-anti-gp120 immune complexes to HIV-1-infected quiescent peripheral blood mononuclear cells reveals latent infection. J Immunol 1996; 156: 3994-4004.
141. Rubartelli A, Poggi A, Sitia R, Zocchi MR. HIV-I Tat: a polypeptide for all seasons. Immunol Today 1998; 19: 543-5.
142. Schibeci SD, Clegg AO, Biti RA, Sagawa K, Stewart GJ, Williamson P. HIV-Nef enhances interleukin-2 production and phosphatidylinositol 3-kinase activity in a human T cell line. AIDS 2000; 14: 1701-7.
143. Wang JK, Kiyokawa E, Verdin E, Trono D. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci USA 2000; 97: 394-9.
144. Krautkrämer E, Giese SI, Gasteier JE, Muranyi W, Fackler OT. Human immunodeficiency virus type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J Virol 2004; 78: 4085-97.
145. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996; 2: 960-4.
146. Schrager JA, Marsh JW. HIV-1 Nef increases T cell activation in a stimulus-dependent manner. Proc Natl Acad Sci USA 1999; 96: 8167-72.
147. Schwartz O, Arenzana-Seisdedos F, Heard JM, Danos O. Activation pathways and human immunodeficiency virus type 1 replication are not altered in CD4+ T cells expressing the nef protein. AIDS Res Hum Retroviruses 1992; 8: 545-51.
148. Carreer R, Groux H, Ameisen JC, Capron A. Role of HIV-1 Nef expression in activation pathways in CD4+ T cells. AIDS Res Hum Retroviruses 1994; 10: 523-7.
149. Simmons A, Aluvihare V, McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 2001; 14: 763-77.
150. Reddy M, Eirikis E, Davis C, Davis HM, Prabhakar U. Comparative analysis of lymphocyte activation marker expression and cytokine secretion profile in stimulated human peripheral blood mononuclear cell cultures: an in vitro model to monitor cellular immune function. J Immunol Methods 2004; 293: 127-42.
151. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside- and nucleotide-analogue reversetranscriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38: 743-53.
152. Tabucchi A, Carlucci F, Consolmagno E, Re MC, Monari P, Marinello E, et al. Purine nucleotide content in human T4 and T8 lymphocyte subpopulations from normal subjects and AIDS patients. Biochem Soc Trans 1992; 20: 377S.
153. Tabucchi A, Carlucci F, Re MC, Furlini G, Consolmagno E, Leoncini R, et al. The behavior of free purine nucleotides in lymphocytes infected with HIV-1 virus. Biochim Biophys Acta 1993; 1182: 317-22.
154. Tabucchi A, Carlucci F, Consolmagno E, Monari P, Re MC, Marinello E, et al. Changes in purine nucleotide content in the lymphocyte subpopulations of patients infected with HIV. Clin Chim Acta 1994; 225: 147-53.
155. Boggiano CA, Carlucci F, Tabucchi A, Pagani R, Marinello E, Pizzichini M, et al. Changes of Purine Nucleotide Content in Lymphocytes from Patients Infected with Human Immunodeficiency Virus. In: Sahota A,
156. Coffin JM. Genetic diversity and evolution of retroviruses. Curr Top Microbiol Immunol 1992; 176: 143-64.
157. Quiñones-Mateu ME, Arts EJ. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist Update 2002; 5: 224-33.
158. Goodenow MM, Rose SL, Tuttle DL, Sleasman JW. HIV-1 fitness and macrophages. J Leukoc Biol 2003; 74: 657-66.
159. Menéndez-Arias L, Martínez MA, Quiñones-Mateu ME, Martinez-Picado J. Fitness variations and their impact on the evolution of antiretroviral drug resistance. Curr Drug Targets Infect Disord 2003; 3: 355-71.
160. Mansky LM. Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res Hum Retroviruses 1996; 12: 307-14.
161. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
162. Richman DD. Selection of zidovudine-resistant variants of human immunodeficiency virus by therapy. Curr Top Microbiol Immunol 1992; 176: 131-42.
163. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IV, et al. HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy. Lancet 1995; 345: 820-4.
164. Smith MS, Brian EL, Pagano JS. Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol 1987; 61: 3769-73.
165. Medina DJ, Tung PP, Lerner-Tung MB, Nelson CJ, Mellors JW, Strair RK. Sanctuary growth of human immunodeficiency virus in the presence of 3′-azido-3′-deoxythymidine. J Virol 1995; 69: 1606-11.
166. Medina DJ, Tung PP, Nelson CJ, Sathya B, Casareale D, Strair RK. Characterization and use of a recombinant retroviral system for the analysis of drug resistant HIV. J Virol Methods 1998; 71: 169-76.
167. Medina DJ, Tung PP, Strair RK. Use of recombinant viruses to assess the pattern of early human immunodeficiency virus break-through infection in the presence of stavudine. J Gen Virol 1999; 80: 2361-7.
168. Crowe SM, Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. J Leukoc Biol 2000; 68: 345-50.
169. Ruibal-Ares B, Belmonte L, Baré P, Bayo-Hanza C, Mendez G, Perez-Bianco R, et al. Monocyte differentiation and HIV replication after prolonged culture of peripheral blood mononuclear cells from HIV-infected individuals. Cell Immunol 2001; 210: 11-20.
170. Belmonte L, Baré P, Picchio GR, Perez-Bianco R, de Tezanos Pinto M, Corti M, et al. Decreased recovery of replication-competent HIV-1 from peripheral blood mononuclear cell-derived monocyte/macrophages of HIV-positive patients after 3 years on highly active antiretroviral therapy. AIDS 2002; 16: 1289-92.
171. Potter SJ, Dwyer DE, Saksena NK. Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. Virology 2003; 305: 339-52.
172. Weinberg JB, Matthews TJ, Cullen BR, Malim MH. Productive human immunodeficiency virus type 1 (HIV-1) infection of non-proliferating human monocytes. J Exp Med 1991; 174: 1477-82.
173. Malaspina A, Moir S, Nickle DC, Donoghue ET, Ogwaro KM, Ehler LA, et al. Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma. J Virol 2002; 76: 8855-63.
174. Chun TW, Davey RT, Jr., Ostrowski M, Justement JS, Engel D, Mullins JI, et al. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med 2000; 6: 757-61.
175. Zhang L, Chung C, Hu BS, He T, Guo Y, Kim AJ, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106: 839-45.
176. Davey RT, Jr., Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999; 96: 15109-14.
177. Bi X, Gatanaga H, Ida S, Tsuchiya K, Matsuoka-Aizawa S, Kimura S, et al. Emergence of protease inhibitor resistance-associated mutations in plasma HIV-1 precedes that in proviruses of peripheral blood mononuclear cells by more than a year. J Acquir Immune Defic Syndr 2003; 34: 1-6.
178. Fulcher JA, Hwangbo Y, Zioni R, Nickle D, Lin X, Heath L, et al. Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection. J Virol 2004; 78: 7883-93.
179. Magierowska M, Bernardin F, Garg S, Staprans S, Miller MD, Van Rompay KK, et al. Highly uneven distribution of tenofovir-selected simian immunodeficiency virus in different anatomical sites of rhesus macaques. J Virol 2004; 78: 2434-44.
180. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 2004; 10(32): 4039-53.
181. Melroy J, Nair V. The antiviral activity, mechanism of action, clinical significance and resistance of abacavir in the treatment of pediatric AIDS. Curr Pharm Des 2005; 11(29): 3847-52.
182. Venkatachalam TK, Goodman PA, Qazi S, D'Cruz O, Uckun FM. Rational drug design of multifunctional phosphoramidate substituted nucleoside analogs. Curr Pharm Des 2004; 10(15): 1713-26.